FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology

April 24, 2024

https://www.globenewswire.com/news-release/2024/04/24/2869054/33525/en/FibroGen-Announces-Clinical-Data-from-Dose-Escalation-Phase-1b-Study-of-FG-3246-FOR46-in-Combination-with-Enzalutamide-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Can.html

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.